Williams Laura A sold $490K of ARDX
Williams Laura A (Chief Patient Officer) sold 81,898 shares of ARDELYX, INC. (ARDX) at $5.99 ($0.49M total) on 2026-06-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price, and post-transaction holdings by the company’s Chief Patient Officer under a 10b5-1 plan.
Market read
This provides a transparent datapoint on insider selling, but the 10b5-1 structure limits interpretability for trading decisions.
What to watch
Traders may over-weight insider sales; the more actionable signal would be subsequent buys, changes in guidance, or clinical/regulatory updates rather than routine Form 4 activity.
Background
The article is an SEC Form 4 insider transaction disclosure for ARDELYX, INC. (ARDX).
Ticker impact
SEC Form 4 shows ARDX Chief Patient Officer Laura Williams sold 81,898 shares for about $490.5K under a 10b5-1 plan.
Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.
The filing is a disclosed open-market sale by an officer with a pre-arranged 10b5-1 plan, which reduces the informational content versus discretionary selling.
Market effects
Minimal; this is company-specific insider transaction with no sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be largely mechanical and not a bearish signal at all.
Key entities
- public_companyARDX
Ardelyx, Inc.; subject of the Form 4 insider transaction disclosure.
- insiderLaura Williams
Chief Patient Officer who sold 81,898 shares under a 10b5-1 plan.